Sökning: onr:"swepub:oai:gup.ub.gu.se/53902" >
Bone-targeted radiu...
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
-
- Nilsson, S. (författare)
- Karolinska Institutet,Karolinska Hospital, Stockholm, Sweden, Karolinska Institute, Stockholm, Sweden
-
- Franzén, Lars (författare)
- Franzén, L., Länssjukhuset Sundsvall-Härnösand, Sundsvall, Sweden
-
- Parker, C. (författare)
- Institute of Cancer Research, Royal Marsden Hospital, Sutton, United Kingdom
-
visa fler...
-
- Tyrrell, C. (författare)
- Plymouth General Hospital, Plymouth, United Kingdom
-
- Blom, R. (författare)
- Östergötlands Läns Landsting
-
- Tennvall, Jan (författare)
- Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,University Hospital Lund, Lund, Sweden
-
- Lennernäs, Bo, 1963 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences,Lennernäs, B., Sahlgrenska University Hospital, Gothenburg, Sweden
-
- Petersson, U. (författare)
- Centrallasarettet i Västerås, Västerås, Sweden
-
- Johannessen, D. C. (författare)
- Haukeland University Hospital, Bergen, Norway
-
- Sokal, M. (författare)
- Nottingham City Hospital, Nottingham, United Kingdom
-
- Pigott, K. (författare)
- Royal Free Hospital, London, United Kingdom
-
- Yachnin, J. (författare)
- Karolinska Institutet,Karolinska Hospital, Stockholm, Sweden
-
- Garkavij, Michael (författare)
- Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,University Hospital Lund, Lund, Sweden
-
- Strang, P. (författare)
- Karolinska Institutet,Karolinska Institute, Stockholm, Sweden
-
- Harmenberg, J. (författare)
- Karolinska Institute, Stockholm, Sweden, Algeta ASA, Oslo, Norway
-
- Bolstad, B. (författare)
- Algeta ASA, Oslo, Norway
-
- Bruland, O. S. (författare)
- Bruland, Ø.S., University of Oslo, Norwegian Radium Hospital, Oslo, Norway
-
visa färre...
-
(creator_code:org_t)
- 2007
- 2007
- Engelska.
-
Ingår i: Lancet Oncol. - 1470-2045 .- 1474-5488. ; 8:7, s. 587-594
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
https://urn.kb.se/re...
-
http://kipublication...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: The alpha-emitter radium-223 ((223)Ra) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone-refractory prostate cancer. We aimed to study mature outcomes from a randomised, multicentre, phase II study of (223)Ra. METHODS: Patients with hormone-refractory prostate cancer and bone pain needing external-beam radiotherapy were assigned to four intravenous injections of (223)Ra (50 kBq/kg, 33 patients) or placebo (31 patients), given every 4 weeks. Primary endpoints were change in bone-alkaline phosphatase (ALP) concentration and time to skeletal-related events (SREs). Secondary endpoints included toxic effects, time to prostate-specific-antigen (PSA) progression, and overall survival. All tests were done at a 5% significance level, based on intention to treat. FINDINGS: Median relative change in bone-ALP during treatment was -65.6% (95% CI -69.5 to -57.7) and 9.3% (3.8-60.9) in the (223)Ra group and placebo groups, respectively (p<0.0001, Wilcoxon ranked-sums test). Hazard ratio for time to first SRE, adjusted for baseline covariates, was 1.75 (0.96-3.19, p=0.065, Cox regression). Haematological toxic effects did not differ significantly between two groups. No patient discontinued (223)Ra because of treatment toxicity. Median time to PSA progression was 26 weeks (16-39) versus 8 weeks (4-12; p=0.048) for (223)Ra versus placebo, respectively. Median overall survival was 65.3 weeks (48.7-infinity) for (223)Ra and 46.4 weeks (32.1-77.4) for placebo (p=0.066, log rank). The hazard ratio for overall survival, adjusted for baseline covariates was 2.12 (1.13-3.98, p=0.020, Cox regression). INTERPRETATION: (223)Ra was well tolerated with minimum myelotoxicity, and had a significant effect on bone-ALP concentrations. Larger clinical trials are warranted to study (223)Ra on the prevention of SREs and on overall survival in patients with hormone-refractory prostate cancer. Bone-targeting properties of (223)Ra could also potentially be used for treating skeletal metastasis from other primary cancers.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Adenocarcinoma/radiotherapy/secondary
- Aged
- Aged
- 80 and over
- Alkaline Phosphatase/blood
- Bone Neoplasms/*radiotherapy/secondary
- Double-Blind Method
- *Drug Resistance
- Neoplasm
- Humans
- Male
- Middle Aged
- Placebos
- Prognosis
- Prostate-Specific Antigen
- Prostatic Neoplasms/pathology/*radiotherapy
- Radium/*therapeutic use
- Survival Rate
- NATURAL SCIENCES
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Nilsson, S.
-
Franzén, Lars
-
Parker, C.
-
Tyrrell, C.
-
Blom, R.
-
Tennvall, Jan
-
visa fler...
-
Lennernäs, Bo, 1 ...
-
Petersson, U.
-
Johannessen, D. ...
-
Sokal, M.
-
Pigott, K.
-
Yachnin, J.
-
Garkavij, Michae ...
-
Strang, P.
-
Harmenberg, J.
-
Bolstad, B.
-
Bruland, O. S.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Lancet Oncol
-
The Lancet Oncol ...
- Av lärosätet
-
Göteborgs universitet
-
Lunds universitet
-
Umeå universitet
-
Karolinska Institutet
-
Linköpings universitet